These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 36468832)

  • 1. Effects of dopamine D2/3 and opioid receptor antagonism on the trade-off between model-based and model-free behaviour in healthy volunteers.
    Mikus N; Korb S; Massaccesi C; Gausterer C; Graf I; Willeit M; Eisenegger C; Lamm C; Silani G; Mathys C
    Elife; 2022 Dec; 11():. PubMed ID: 36468832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dopamine D2/3- and μ-opioid receptor antagonists reduce cue-induced responding and reward impulsivity in humans.
    Weber SC; Beck-Schimmer B; Kajdi ME; Müller D; Tobler PN; Quednow BB
    Transl Psychiatry; 2016 Jul; 6(7):e850. PubMed ID: 27378550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Computational modelling reveals contrasting effects on reinforcement learning and cognitive flexibility in stimulant use disorder and obsessive-compulsive disorder: remediating effects of dopaminergic D2/3 receptor agents.
    Kanen JW; Ersche KD; Fineberg NA; Robbins TW; Cardinal RN
    Psychopharmacology (Berl); 2019 Aug; 236(8):2337-2358. PubMed ID: 31324936
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The antinociceptive effect of amisulpride in mice is mediated through opioid mechanisms.
    Weizman T; Pick CG; Backer MM; Rigai T; Bloch M; Schreiber S
    Eur J Pharmacol; 2003 Oct; 478(2-3):155-9. PubMed ID: 14575800
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential modulation of reinforcement learning by D2 dopamine and NMDA glutamate receptor antagonism.
    Jocham G; Klein TA; Ullsperger M
    J Neurosci; 2014 Sep; 34(39):13151-62. PubMed ID: 25253860
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dopaminergic and opioidergic regulation during anticipation and consumption of social and nonsocial rewards.
    Korb S; Götzendorfer SJ; Massaccesi C; Sezen P; Graf I; Willeit M; Eisenegger C; Silani G
    Elife; 2020 Oct; 9():. PubMed ID: 33046213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential effects of dopamine D1 and D 2/3 receptor antagonism on motor responses.
    Tran S; Nowicki M; Muraleetharan A; Gerlai R
    Psychopharmacology (Berl); 2015 Feb; 232(4):795-806. PubMed ID: 25134500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dopaminergic Modulation of Human Intertemporal Choice: A Diffusion Model Analysis Using the D2-Receptor Antagonist Haloperidol.
    Wagner B; Clos M; Sommer T; Peters J
    J Neurosci; 2020 Oct; 40(41):7936-7948. PubMed ID: 32948675
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Facial mimicry is not modulated by dopamine D2/3 and opioid receptor antagonism.
    Korb S; Clarke A; Massaccesi C; Willeit M; Silani G
    Psychopharmacology (Berl); 2023 Oct; 240(10):2081-2091. PubMed ID: 37477676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute antagonism of dopamine D2-like receptors by amisulpride: effects on hormone secretion in healthy volunteers.
    Wetzel H; Wiesner J; Hiemke C; Benkert O
    J Psychiatr Res; 1994; 28(5):461-73. PubMed ID: 7897617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of pharmacological manipulation of dopamine and opioid receptor subtypes on stereotyped behaviour of restricted-fed fowls.
    Kostal L; Savory CJ
    Pharmacol Biochem Behav; 1994 May; 48(1):241-52. PubMed ID: 8029296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity.
    Schoemaker H; Claustre Y; Fage D; Rouquier L; Chergui K; Curet O; Oblin A; Gonon F; Carter C; Benavides J; Scatton B
    J Pharmacol Exp Ther; 1997 Jan; 280(1):83-97. PubMed ID: 8996185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic-like activity in rodent models: I. neurochemical characterisation of RG-15.
    Kiss B; Laszlovszky I; Horváth A; Némethy Z; Schmidt E; Bugovics G; Fazekas K; Gyertyán I; Agai-Csongor E; Domány G; Szombathelyi Z
    Naunyn Schmiedebergs Arch Pharmacol; 2008 Nov; 378(5):515-28. PubMed ID: 18551280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is regionally selective D2/D3 dopamine occupancy sufficient for atypical antipsychotic effect? an in vivo quantitative [123I]epidepride SPET study of amisulpride-treated patients.
    Bressan RA; Erlandsson K; Jones HM; Mulligan R; Flanagan RJ; Ell PJ; Pilowsky LS
    Am J Psychiatry; 2003 Aug; 160(8):1413-20. PubMed ID: 12900302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Opioid antagonism modulates wanting-related frontostriatal connectivity.
    Soutschek A; Weber SC; Kahnt T; Quednow BB; Tobler PN
    Elife; 2021 Nov; 10():. PubMed ID: 34761749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of dopamine and opioid receptor antagonism on the neural processing of social and nonsocial rewards.
    Massaccesi C; Korb S; Götzendorfer S; Chiappini E; Willeit M; Lundström JN; Windischberger C; Eisenegger C; Silani G
    Hum Brain Mapp; 2024 Mar; 45(4):e26645. PubMed ID: 38445523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amisulpride a selective dopamine antagonist and atypical antipsychotic: results of a meta-analysis of randomized controlled trials.
    Leucht S
    Int J Neuropsychopharmacol; 2004 Mar; 7 Suppl 1():S15-20. PubMed ID: 14972080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo extrastriatal and striatal D2 dopamine receptor blockade by amisulpride in schizophrenia.
    Xiberas X; Martinot JL; Mallet L; Artiges E; Canal M; Loc'h C; Mazière B; Paillère-Martinot ML
    J Clin Psychopharmacol; 2001 Apr; 21(2):207-14. PubMed ID: 11270918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity.
    Perrault G; Depoortere R; Morel E; Sanger DJ; Scatton B
    J Pharmacol Exp Ther; 1997 Jan; 280(1):73-82. PubMed ID: 8996184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dopamine-mediated reinforcement learning signals in the striatum and ventromedial prefrontal cortex underlie value-based choices.
    Jocham G; Klein TA; Ullsperger M
    J Neurosci; 2011 Feb; 31(5):1606-13. PubMed ID: 21289169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.